The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

Myasthenia Gravis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted myasthenia gravis epidemiology in the 7MM, i.e., the United ...

On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and placebo scores was -2.8 points (95% CI -3.9 to -1.7, P=0.001) at 52 weeks ...

HCRU: Economic Burden of Myasthenia Gravis Exacerbation and Crisis from US Payer Perspective. Session 7 #11-029. Date: Monday, April 7. Presentation Time: 5:00 PM – 6:00 PM ...

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in ...

Generalized Myasthenia Gravis Session 9 #11-034. Date: Tuesday, April 8. Presentation Time: 11:45 AM – 12:45 PM HCRU: Economic Burden of Myasthenia Gravis Exacerbation and Crisis from US Payer ...

Important risk factors identified for exacerbation or symptom worsening included living alone, generalized MG symptomology, and comorbid anxiety/depression. These findings underscore the ongoing ...

Spotlight On > gMG Myasthenia Gravis Exacerbations — Emerging treatments focus on more precise immune modulation. by Paul Smyth, MD, Contributing Writer, MedPage Today March 7, 2025 • 4 min read ...

In myasthenia gravis (MG), IVIG can be used in a few different ways: To treat acute exacerbations: IVIG is often used to treat acute exacerbations because improvements are typically seen in less ...